NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Halder Venture Credit Rating Upgraded to 'CRISIL BBB-/Stable' on Improved Financial Performance
CRISIL has upgraded Halder Venture Limited's long-term rating to 'CRISIL BBB-/Stable' from 'CRISIL BB+/Stable (Issuer Not Cooperating)' following improved data transparency and strong financial growth. The company reported a significant revenue jump to Rs 870.88 crore in FY25, with PAT nearly doubling to Rs 21.11 crore. While the group maintains a moderate financial risk profile with a gearing of 1.94x, it is currently executing a large Rs 155 crore capex for a new refinery and storage unit in Haldia. Liquidity is considered adequate with projected cash accruals of over Rs 22 crore against debt obligations of Rs 5 crore.
முக்கிய அம்சங்கள்
Long-term credit rating upgraded to 'CRISIL BBB-/Stable' for Rs 387.27 crore bank facilities.FY25 operating income grew to Rs 870.88 crore from Rs 646.19 crore in FY24.Net profit (PAT) increased to Rs 21.11 crore in FY25 compared to Rs 11.67 crore in FY24.Ongoing Rs 155 crore capex in Haldia for storage and refinery units, funded by Rs 75 crore debt.Interest coverage ratio improved to 2.55 times in FY25 from 2.11 times in FY24.
👀 கவனிக்க வேண்டியவை
The rating upgrade and removal from the 'non-cooperating' category signal improved corporate governance and creditworthiness. Investors should monitor the timely commissioning of the Haldia refinery in 2027, as it is a key driver for future margin expansion.
Halder Venture to Raise ₹25 Crore via Preferential Issue of 7.93 Lakh Warrants at ₹315
Halder Venture Limited is seeking shareholder approval to raise approximately ₹25 crore through the issuance of 7,93,650 convertible warrants to P.K. Bio Link Pvt. Ltd., a non-promoter entity. The warrants are priced at ₹315 each, which includes a premium of ₹305 per share. To facilitate this, the company is also proposing to increase its authorized share capital from ₹13.425 crore to ₹18.425 crore. This capital infusion is intended to support the company's growth and operational needs.
முக்கிய அம்சங்கள்
Proposed issuance of 7,93,650 convertible warrants to non-promoter P.K. Bio Link Pvt. Ltd.Total fundraise amount fixed at ₹24,99,99,750 at an issue price of ₹315 per warrant.Authorized share capital to be increased by ₹5 crore to a total of ₹18.425 crore.Warrant holders must pay 25% of the total consideration upfront, with the remaining 75% due within 18 months upon conversion.Independent valuation report determined a minimum price of ₹314.79 per equity share, supporting the ₹315 issue price.
👀 கவனிக்க வேண்டியவை
The fundraise at a premium suggests confidence from external investors; however, existing shareholders should monitor the potential equity dilution of over 5% upon warrant conversion.
Haleos Labs Seeks Approval for ₹20 Crore Corporate Guarantee for Subsidiary Mahi Drugs
Haleos Labs Limited has issued a postal ballot notice to seek shareholder approval for a material related party transaction. The company intends to provide a corporate guarantee of up to USD 2.2 million (approximately ₹20 crores) in favor of RBL Bank. This guarantee is required to secure an External Commercial Borrowing (ECB) facility for its subsidiary, Mahi Drugs Private Limited. Shareholders can cast their votes via remote e-voting between March 31 and April 29, 2026.
முக்கிய அம்சங்கள்
Proposed corporate guarantee of USD 2.2 million (approx. ₹20 crores) for subsidiary Mahi Drugs Private LimitedGuarantee to secure External Commercial Borrowing (ECB) facility from RBL BankShareholder approval sought via postal ballot through remote e-voting processE-voting period scheduled from March 31, 2026, to April 29, 2026Final results of the postal ballot to be declared on May 1, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the parent company's contingent liabilities and the performance of Mahi Drugs to ensure the debt is well-serviced. This move indicates financial support for subsidiary expansion but increases the parent's risk profile.
Halder Venture to Raise ₹25 Crore via Preferential Issue of Convertible Warrants
Halder Venture Limited's board has approved a significant fundraise of approximately ₹25 crore through the issuance of 7,93,650 convertible warrants. These warrants are priced at ₹315 each (including a ₹305 premium) and will be allotted to P.K. Bio Link Private Limited, a non-promoter entity. To accommodate this issuance, the company is increasing its authorized share capital from ₹13.425 crore to ₹18.425 crore. Additionally, the company has transitioned its internal audit function to M/s J Kumar Jain & Associates following the resignation of the previous auditor.
முக்கிய அம்சங்கள்
Approved issuance of 7,93,650 convertible warrants at ₹315 per warrant to raise ₹24.99 crore.Authorized share capital increased from ₹13.425 crore to ₹18.425 crore to facilitate the issue.Preferential allotment targeted at a single non-promoter investor, P.K. Bio Link Private Limited.Appointment of M/s J Kumar Jain & Associates as Internal Auditor for the financial year 2025-2026.The fundraise and capital increase are subject to shareholder approval via postal ballot.
👀 கவனிக்க வேண்டியவை
Investors should view the ₹25 crore capital infusion as a positive indicator for growth and monitor the company's upcoming postal ballot for shareholder approval. The warrant pricing at ₹315 serves as a key valuation benchmark for the stock.
Halder Venture to Raise ₹25 Crore via Warrants; Increases Authorised Capital to ₹18.42 Crore
Halder Venture Limited has approved a significant fundraise of approximately ₹25 crore through the preferential issuance of 7,93,650 convertible warrants to a non-promoter entity, P.K. Bio Link Private Limited. To accommodate this and future requirements, the company is increasing its authorised share capital from ₹13.42 crore to ₹18.42 crore. The warrants are priced at ₹315 each, representing a substantial premium of ₹305 over the face value. Additionally, the company has appointed M/s J Kumar Jain & Associates as the new internal auditor for FY 2025-26.
முக்கிய அம்சங்கள்
Approved issuance of 7,93,650 convertible warrants at ₹315 per warrant, totaling ₹24.99 crore.Authorised share capital increased by ₹5 crore to a new total of ₹18.425 crore.Preferential allotment is being made to a non-promoter investor, P.K. Bio Link Private Limited.Warrant conversion price includes a premium of ₹305 per share on a face value of ₹10.Appointment of M/s J Kumar Jain & Associates as Internal Auditor following the resignation of the previous firm.
👀 கவனிக்க வேண்டியவை
Investors should view the fundraise at a significant premium as a positive indicator of valuation and growth potential. Monitor the upcoming postal ballot results for shareholder approval and subsequent updates on the utilization of these funds.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Haleos Labs Seeks Shareholder Approval for Corporate Guarantee to Subsidiary Mahi Drugs
Haleos Labs Limited has initiated a Postal Ballot process to seek shareholder approval for a material related party transaction. The company intends to provide a corporate guarantee to RBL Bank to secure External Corporate Borrowing (ECB) facilities for its subsidiary, Mahi Drugs Private Limited. The e-voting period is scheduled to run from March 31, 2026, to April 29, 2026, with final results to be declared on May 1, 2026. This move highlights the parent company's financial support for its subsidiary's capital requirements.
முக்கிய அம்சங்கள்
Proposed ordinary resolution for a corporate guarantee to RBL Bank for subsidiary Mahi Drugs Private Limited.The transaction is categorized as a Material Related Party Transaction under SEBI regulations.Cut-off date for shareholder voting eligibility is March 27, 2026.E-voting window is open for 30 days from March 31 to April 29, 2026.Postal ballot results will be officially declared on May 1, 2026.
👀 கவனிக்க வேண்டியவை
Investors should evaluate the financial health of the subsidiary, Mahi Drugs, as this guarantee increases the contingent liabilities of Haleos Labs. Monitor the final voting results on May 1 to confirm the approval of this financial arrangement.
Kaushalya Infrastructure Receives ₹5.46 Crore Income Tax Demand for AY 2017-18 to 2023-24
Kaushalya Infrastructure Development Corporation has received assessment orders and demand notices from the Income Tax Department totaling ₹5.46 crore. The notices span seven assessment years from 2017-18 to 2023-24, issued under Section 147 and 144 of the IT Act. The department has treated certain amounts as deemed income, which the company intends to contest before appellate authorities. While the company claims no significant impact on operations, the demand represents a potential financial liability.
முக்கிய அம்சங்கள்
Total tax demand of ₹5,45,61,668 issued by the Deputy Commissioner of Income Tax, New Delhi.The demand covers a continuous seven-year period from Assessment Year 2017-18 to 2023-24.Orders were passed under Section 147 read with Section 144 of the Income-tax Act, 1961.The company is evaluating the orders and plans to pursue legal remedies through appellate authorities.Management believes they have strong legal and factual grounds to challenge the adjustments.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the company's appeal as a ₹5.46 crore liability could be material for a company of this size. Watch for any provisions made in upcoming quarterly results related to this tax dispute.
Halder Venture to Consider Fundraising via Preferential Issue on March 26, 2026
Halder Venture Limited has scheduled a Board Meeting for March 26, 2026, to deliberate on two major corporate actions. The primary agenda includes a proposal for raising funds through a preferential issue of securities, which often signals expansion or debt reduction. Additionally, the board will consider an increase in the company's authorized share capital to facilitate this issuance. Investors should note that the trading window for insiders has been closed effective March 26 until 48 hours after the meeting results are disclosed.
முக்கிய அம்சங்கள்
Board meeting scheduled for March 26, 2026, to approve fundraising via preferential issue.Proposal to increase the authorized share capital of the company to be discussed.Trading window for promoters and designated persons closed from March 26, 2026.The meeting is set to take place at the company's Kolkata office at 3:00 P.M.
👀 கவனிக்க வேண்டியவை
Investors should wait for the board meeting outcome to understand the quantum of funds being raised and the issue price. A preferential issue to strategic investors can be a positive catalyst, though it may lead to equity dilution.
Shalby Launches Advanced Oncology and Radiotherapy Department at Krishna Shalby Hospital
Shalby Limited has announced the inauguration of a specialized Oncology Department at its Krishna Shalby Hospital in Ahmedabad. This new facility includes advanced Radiotherapy services, allowing for comprehensive cancer treatment under one roof. The department is staffed by a multidisciplinary team of medical, radiation, and surgical oncologists to provide integrated care. This expansion into high-specialty services is expected to enhance the hospital's service mix and competitive positioning in the Ahmedabad region.
முக்கிய அம்சங்கள்
Inauguration of a new Oncology Department at Krishna Shalby Hospital, AhmedabadAddition of advanced Radiotherapy facilities to provide integrated cancer careDeployment of a multidisciplinary team including medical, radiation, and surgical oncologistsStrategic focus on providing comprehensive diagnosis and treatment at a single location to improve patient outcomes
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development as oncology is a high-margin specialty that can drive higher Average Revenue Per Occupied Bed (ARPOB). Monitor the company's upcoming quarterly results for improvements in specialized treatment volumes.
Marshall Machines 6th CoC Meeting: Voting on Revised Resolution Plan and PUFE Status Update
Marshall Machines Limited has scheduled its 6th Committee of Creditors (CoC) meeting for March 20, 2026, as part of its ongoing Corporate Insolvency Resolution Process (CIRP). The meeting will address critical updates on asset valuation and the status of PUFE (Preferential, Undervalued, Fraudulent, or Extortionate) applications filed before the NCLT. Significantly, the CoC will vote on a revised resolution plan received via a Swiss Challenge mechanism. The committee will also discuss delays in the submission of Earnest Money Deposits (EMD) and resolution plans by a specific group of joint bidders.
முக்கிய அம்சங்கள்
6th CoC meeting convened for March 20, 2026, to progress the insolvency resolution process.Voting scheduled for a revised resolution plan received following a Swiss Challenge mechanism.Discussion on delays in EMD and plan submission by joint bidders Mr. Anuj Goyal, Ms. Mona Vij, and Mr. Amrit Kumar Agrawal.Updates on the status of asset valuation and the filing of PUFE applications before the Hon'ble NCLT.Review of updated claims and recommendation for inclusion of additional claims in the CIRP.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company is in insolvency, which typically leads to significant equity dilution or total loss for shareholders. Monitor the outcome of the CoC's vote on the resolution plan to understand the potential recovery or liquidation scenario.
Vaishali Pharma Shareholders Approve Preferential Issue of Equity Shares
Vaishali Pharma Limited has received shareholder approval through a postal ballot for the issuance and allotment of equity shares on a preferential basis. The special resolution was passed with an overwhelming majority, with 99.99% of the votes cast in favor by participating public shareholders. Promoters and the promoter group abstained from voting as they were interested parties in the resolution. This approval clears the path for the company to raise capital, which is typically used for expansion or strengthening the balance sheet.
முக்கிய அம்சங்கள்
Special Resolution for issuing equity shares on a preferential basis was approved by shareholders.The resolution received 99.9909% votes in favor from the public non-institutional category.A total of 25,415,321 votes were polled during the postal ballot process.Promoters and promoter group members abstained from voting due to their interest in the resolution.The record date for determining eligibility for the postal ballot was February 6, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor upcoming disclosures regarding the specific allotment price and the list of allottees to evaluate the impact of equity dilution. The successful approval indicates strong shareholder support for the company's fundraising and growth plans.
Simbhaoli Sugars' Interim Resolution Professional (IRP) has recorded the FY25 consolidated financial results, which have received an 'Adverse Opinion' from statutory auditors. The auditors cited significant 'Going Concern' uncertainties, including a year-long turbine breakdown at its power subsidiary and lack of financial support. Major financial discrepancies were noted, such as ₹1,116.19 Lakhs in disputed receivables and ₹462.57 Lakhs in unprovided doubtful debts at subsidiaries. The company remains under the Insolvency and Bankruptcy Code (IBC) with a critical NCLAT hearing scheduled for March 24, 2026.
முக்கிய அம்சங்கள்
Statutory auditors issued an 'Adverse Opinion' on the FY25 consolidated financial results due to pervasive accounting issues.Subsidiary SPPL faces 'Going Concern' doubts following a year-long turbine failure and ₹1,116.19 Lakhs in disputed receivables.Subsidiary ICCPL failed to provide for ₹462.57 Lakhs in disputed unbilled revenue and ₹209.43 Lakhs in receivables overdue for 3+ years.The company is currently under Corporate Insolvency Resolution Process (CIRP) with management controlled by an IRP.NCLAT has stayed further insolvency steps until the next hearing on March 24, 2026, to allow for settlement proposals.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the adverse audit opinion and ongoing insolvency proceedings suggest a high risk of total capital loss. The stock is highly speculative given the significant doubts regarding the company's ability to continue as a going concern.
HAL Reaffirmed CARE AAA; Stable Rating with ₹2.59 Lakh Crore Order Book
CARE Ratings has reaffirmed HAL's highest 'AAA' rating for its ₹6,050 crore bank facilities, reflecting its strategic importance to India's defense sector. The company's order book has nearly doubled to ₹258,942 crore as of September 2025, providing revenue visibility for the next 7-8 years. HAL maintains an exceptionally strong financial profile with ₹43,465 crore in free cash and zero reliance on external debt. Profitability remains healthy with a 29.19% PBILDT margin in FY25 and a future order pipeline estimated up to ₹1 lakh crore.
முக்கிய அம்சங்கள்
CARE reaffirmed 'CARE AAA; Stable / CARE A1+' ratings for ₹6,050 crore bank facilities.Order book surged to ₹258,942 crore as of Sept 30, 2025, compared to ₹133,238 crore in Dec 2024.Strong liquidity position with free cash and equivalents of ₹43,465 crore and customer advances of ₹52,219 crore.FY25 Total Operating Income stood at ₹30,146 crore with a healthy PBILDT margin of 29.19%.Future order pipeline estimated between ₹60,000 crore and ₹1,00,000 crore expected within 1-2 years.
👀 கவனிக்க வேண்டியவை
The rating reaffirmation and massive order book growth reinforce HAL's dominant position in the defense sector. Investors should remain positive given the company's zero-debt status and multi-year revenue visibility.
Shalby Launches Advanced Oncology and Radiotherapy Department at Surat Hospital
Shalby Limited has inaugurated a comprehensive Oncology Department at its Surat multi-specialty hospital. The new facility includes advanced radiotherapy services, enabling the hospital to provide integrated cancer care across medical, surgical, and radiation oncology. This expansion targets the South Gujarat region, aiming to provide specialized diagnosis and treatment under one roof. The addition of high-margin oncology services is expected to enhance the hospital's service mix and potentially improve its Average Revenue Per Occupied Bed (ARPOB).
முக்கிய அம்சங்கள்
Inauguration of a dedicated Oncology Department at Shalby Multi-Specialty Hospital, SuratIntroduction of advanced Radiotherapy facilities for comprehensive cancer treatmentIntegrated care model featuring medical, radiation, and surgical oncology teamsStrategic expansion to capture demand for specialized cancer care in the South Gujarat region
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive operational development that could boost high-margin revenue for the Surat unit. Monitor future quarterly results for improvements in ARPOB and occupancy driven by these specialized services.
HAL Bags Rs 2,901 Crore Order for 6 ALH MK III Helicopters from Ministry of Defence
Hindustan Aeronautics Limited (HAL) has signed a contract worth Rs 2,901 crore with the Ministry of Defence for six ALH MK III (Maritime Role) helicopters. The contract, aimed at the Indian Coast Guard, includes operational equipment, engineering support, and performance-based logistics. This order is part of the 'Buy (Indian-IDDM)' category, promoting domestic defense manufacturing. The project is expected to generate 65 lakh man-hours of employment and involve over 200 MSMEs, strengthening HAL's operational pipeline.
முக்கிய அம்சங்கள்
Total contract value stands at Rs 2,901 crore for 6 Advanced Light Helicopters (ALH) Mk-III.Includes an engineering support package and performance-based logistics support for the Indian Coast Guard.The project will involve over 200 MSMEs and is expected to generate 65 lakh man-hours of employment.The helicopters are designed for maritime security missions from both shore-based airfields and ships at sea.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that bolsters HAL's robust order book and reinforces its leadership in Indian defense aviation. The inclusion of long-term logistics support provides additional revenue visibility beyond the initial delivery.
Shalby Subsidiary PK Healthcare Receives NABH Accreditation Valid Until 2030
Shalby Limited's subsidiary, PK Healthcare Private Limited (Shalby International Hospitals) located in Gurugram, has been granted accreditation by the National Accreditation Board for Hospitals & Healthcare Providers (NABH). The accreditation follows the 6th Edition Standards, which focus on patient safety, clinical governance, and risk management. This certification is valid for a period of four years, extending until 2030. Such accreditations are critical for healthcare providers to maintain quality benchmarks and attract corporate and insurance-linked patients.
முக்கிய அம்சங்கள்
PK Healthcare Pvt Ltd (Gurugram) granted NABH accreditation under the rigorous 6th Edition Standards.The accreditation is valid for a long-term duration until the year 2030.Framework emphasizes patient safety protocols, clinical governance, and continuous quality improvement.Accreditation strengthens the hospital's position in evidence-based clinical care and infection control.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive operational milestone that validates the quality of healthcare services at Shalby's Gurugram facility. This accreditation is likely to improve the hospital's reputation and operational efficiency, supporting long-term revenue growth.
Chalet Hotels Ranks 2nd Globally in DJSI 2025 with Improved Score of 82
Chalet Hotels Limited has achieved a significant milestone in its ESG performance, scoring 82 in the 2025 S&P Global Corporate Sustainability Assessment (CSA), a substantial increase from 67 in the previous year. The company is now ranked 2nd globally among 80 companies in the Hotels, Resorts & Cruise Lines category. The score breakdown shows strong performance across all pillars: Environment (85), Social (83), and Governance & Economic (78). This improvement enhances the company's profile for institutional and ESG-focused investors.
முக்கிய அம்சங்கள்
Total DJSI score improved to 82 in 2025 from 67 in the previous yearRanked 2nd worldwide out of 80 companies in the Hotels, Resorts & Cruise Lines categoryAchieved high individual pillar scores: Environment (85), Social (83), and Governance & Economic (78)Demonstrates significant progress in corporate sustainability and ESG compliance
👀 கவனிக்க வேண்டியவை
Investors should recognize this as a positive development that strengthens the company's appeal to ESG-mandated funds and long-term institutional investors. No immediate trading action is required, but it reinforces the company's operational quality.
Marshall Machines 5th CoC Meeting: Resolution Plan De-sealed and Transaction Audit Discussed
Marshall Machines Limited is currently undergoing the Corporate Insolvency Resolution Process (CIRP), with the 5th Committee of Creditors (CoC) meeting held on February 26, 2026. A significant development is the de-sealing of a Resolution Plan submitted by a prospective applicant, indicating progress toward a potential turnaround. The CoC also discussed the Transaction Audit Report and the methodology for asset valuation. E-voting on several items, including the non-disclosure of fair value and ratification of costs, is scheduled to conclude on March 5, 2026.
முக்கிய அம்சங்கள்
5th CoC meeting held on February 26, 2026, to progress the insolvency resolution process.De-sealing of a Resolution Plan submitted by a Prospective Resolution Applicant (PRA) was a key agenda item.Discussion held on the Transaction Audit Report and the methodology for valuing the Corporate Debtor's assets.E-voting for agenda items, including CIRP cost ratification, runs from February 28 to March 5, 2026.Proposal to approve non-disclosure of fair value in the Information Memorandum as per new IBBI regulations.
👀 கவனிக்க வேண்டியவை
Investors should remain extremely cautious as the company is in insolvency, which typically results in significant equity dilution or total loss. Monitor the outcome of the resolution plan evaluation to see if the company can successfully emerge from CIRP.
Vaishali Pharma to Acquire 51.02% of Kesar Pharma; Preferential Issue at Rs 20 Per Share
Vaishali Pharma has issued a corrigendum to its postal ballot notice regarding the acquisition of a 51.02% stake in Kesar Pharma Limited. The deal involves a preferential issue of shares at Rs 20 each, which is significantly higher than the SEBI-mandated floor price of Rs 09.46. The floor price was derived from the 90-day volume-weighted average price (VWAP) as per regulatory requirements. Shareholders have until March 15, 2026, to cast or modify their votes based on these updated disclosures.
முக்கிய அம்சங்கள்
Proposed acquisition of a 51.02% majority stake in Kesar Pharma LimitedPreferential shares to be issued at Rs 20 per share, a 111% premium over the floor price of Rs 09.46Floor price based on 90-day VWAP of Rs 09.46 and 10-day VWAP of Rs 08.02Relevant date for the transaction pricing is February 13, 2026E-voting facility for shareholders is open until 05:00 PM on March 15, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful integration of Kesar Pharma as it represents a significant majority acquisition. The high issue price relative to the floor price is a positive signal regarding the company's internal valuation.
Shalby Increases Stake in Subsidiary PK Healthcare to 91.13% via Rs 59.6 Cr Rights Issue
Shalby Limited has increased its stake in its subsidiary, PK Healthcare Private Limited (PKHPL), from 87.26% to 91.13%. The company invested approximately Rs 59.60 crore by subscribing to 5.96 crore equity shares at a price of Rs 10 per share through a rights issue. The capital infusion will be utilized by PKHPL for debt repayment and working capital requirements. PKHPL, which focuses on the Delhi/NCR healthcare market, reported a turnover of Rs 91.19 crore in FY 2024-25.
முக்கிய அம்சங்கள்
Acquired 5,96,01,950 equity shares of PK Healthcare at Rs 10 per shareTotal investment amount stands at Rs 59,60,19,500Shalby's shareholding in PKHPL increased from 87.26% to 91.13%Funds will be used by the subsidiary for debt repayment and working capitalPKHPL's turnover grew from Rs 67.36 crore in FY23 to Rs 91.19 crore in FY25
👀 கவனிக்க வேண்டியவை
This move consolidates control and helps deleverage a key subsidiary in the high-growth Delhi/NCR region. Investors should monitor if this capital infusion leads to improved consolidated margins for Shalby in the coming quarters.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
